BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies
Apoptosis is an essential characteristic of cancer and its dysregular promotes tumor growth, clonal evolution, and treatment resistance. B-cell lymphoma-2 (BCL-2) protein family members are key to the intrinsic, mitochondrial apoptotic pathway. The inhibition of the BCL-2 family pro-survival protein...
Saved in:
Main Authors: | Mariam Markouli, Maria N. Pagoni, Panagiotis Diamantopoulos |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1501950/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia
by: Juan Li, et al.
Published: (2025-12-01) -
miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting
by: Yilan Xu, et al.
Published: (2025-02-01) -
Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia
by: Renshi Kawakatsu, et al.
Published: (2025-01-01) -
Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy
by: Cheng-Yu Tang, et al.
Published: (2023-10-01) -
Anuric Acute Kidney Injury in Chronic Myeloid Leukemia: A Rare Complication Case
by: Angela Kimberly Tjahjadi, et al.
Published: (2024-10-01)